IL-10 measurement in aqueous humor for screening patients with suspicion of primary intraocular lymphoma

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 7, 2007, Pages 3253-3259

  Cassoux, Nathalie ^a   Giron, Alain ^b   Bodaghi, Bahram ^a   Tran, Thi H C ^a   Baudet, Sylvie ^a   Davy, Fréderic ^a   Chan, Chi C ^c   Lehoang, Phuc ^a   Merle Béral, Hélène ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

^c NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; IL10 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYSIS OF VARIANCE; AQUEOUS HUMOR; ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; IDIOPATHIC DISEASE; INTRAOCULAR LYMPHOMA; INTRAOCULAR TUMOR; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANK SUM TEST; RECEIVER OPERATING CHARACTERISTIC; SCREENING; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; TUKEY KRAMER TEST; UVEITIS; VITRECTOMY; ADOLESCENT; B CELL LYMPHOMA; CHILD; EYE TUMOR; LARGE CELL LYMPHOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; ROC CURVE; VITREOUS BODY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AQUEOUS HUMOR; CHILD; EYE NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-10; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; ROC CURVE; SENSITIVITY AND SPECIFICITY; UVEITIS; VITRECTOMY; VITREOUS BODY;

EID: 34447095869     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-0031     Document Type: Article

References (30)

1. Levy-Clarke GA, Buggage RR, Shen D, Vaughn LO, Chan CC, Davis JL. Human T-cell lymphotropic virus type-1 associated t-cell leukemia/lymphoma masquerading as necrotizing retinal vasculitis. Ophthalmology. 2002;109:1717-1722.
2. Siegel MJ, Dalton J, Friedman AH, Strauchen J, Watson C. Ten-year experience with primary ocular 'reticulum cell sarcoma' (large cell non-Hodgkin's lymphoma). Br J Ophthalmol. 1989;73:342-346.
3. Davis J. Diagnosis of intraocular lymphoma. Ocul Immunol Inflamm. 2004;12:7-16.
4. Hochberg FH, Miller D. Primary central nervous system lymphoma. J Neurosurg. 1988;68:835-853.
5. Cassoux N, Merle-Beral H, Leblond V, et al. Ocular and central nervous system lymphoma: clinical features and diagnosis. Ocul Immunol Inflamm. 2000;8:243-250.
6. Corn BW, Marcus SM, Topham A, Hauck W, Curran WJ Jr. Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000? Cancer. 1997;79:2409-2413.
7. Chan CC, Buggage RR, Nussenblatt RB. Intraocular lymphoma. Curr Opin Ophthalmol. 2002;13:411-418.
8. Whitcup SM, de Smet MD, Rubin BI, et al. Intraocular lymphoma: clinical and histopathologic diagnosis. Ophthalmology. 1993;100:1399-1406.
9. Jovasevic VM, Gorelik L, Bluestone JA, Mokyr MB. Importance of IL-10 for CTLA-4-mediated inhibition of tumor-eradicating immunity. J Immunol. 2004;172:1449-1454.
10. Chan CC, Whitcup SM, Solomon D, Nussenblatt RB. Interleukin-10 in the vitreous of patients with primary intraocular lymphoma. Am J Ophthalmol. 1995;120:671-673.
11. Whitcup SM, Stark-Vanes V, Wittes RE, et al. Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma. Arch Ophthalmol. 1997;115:1157-1160.
12. Wolf LA, Reed GF, Buggage RR, Nussenblatt RB, Chan CC. Vitreous cytokine levels. Ophthalmology. 2003;110:1671-1672.
13. Akpek EK, Maca SM, Christen WG, Foster CS. Elevated vitreous interleukin-10 level is not diagnostic of intraocular-central nervous system lymphoma. Ophthalmology. 1999;106:2291-2295.
14. Hormigo A, Abrey L, Heinemann MH, DeAngelis LM. Ocular presentation of primary central nervous system lymphoma:diagnosis and treatment. Br J Haematol. 2004;126:202-208.
15. Merle-Beral H, Davy F, Cassoux N, et al. Biological diagnosis of primary intraocular lymphoma. Br J Haematol. 2004;126:469-473.
16. Wilson DJ, Braziel R, Rosenbaum JT. Intraocular lymphoma. Immunopathologic analysis of vitreous biopsy specimens. Arch Ophthalmol. 1992;110:1455-1458.
17. Shen DF, Zhuang Z, LeHoang P, et al. Utility of microdissection and polymerase chain reaction for the detection of immunoglobulin gene rearrangement and translocation in primary intraocular lymphoma. Ophthalmology. 1998;105:1664-1669.
18. Dawson BK. Basic and Clinical Biostatistics. Norwalk, CT: Appleton and Lange; 1990.
19. Metz C. Statistical Analysis of ROC Data in Evaluating Diagnostic Performance. New York: American Institute of Physics; 1986.
20. Youden W. Index for rating diagnostic test. Cancer. 1950;3:32-35.
21. Helbig H, Noske W, Kleineidam M, Kellner U, Foerster MH. Bacterial endophthalmitis after anterior chamber paracentesis. Br J Ophthalmol. 1995;79:866.
22. Azuara-Blanco A, Katz LJ. Infectious keratitis in a paracentesis tract. Ophthalmic Surg Lasers. 1997;28:332-333.
23. Van der Lelij A, Rothova A. Diagnostic anterior chamber paracentesis in uveitis: a safe procedure? Br J Ophthalmol. 1997;81:976-979.
24. Cheung CM, Durrani OM, Murray PI. The safety of anterior chamber paracentesis in patients with uveitis. Br J Ophthalmol. 2004;88:582-583.
25. Murray PI, Hoekzelma R, van Haren MA, de Hon FD, Kijlstra A. Aqueous humor interleukin-6 levels in uveitis. Invest Ophthalmol Vis Sci. 1990;31:917-920.
26. Buggage RR, Velez G, Myers-Powell B, Shen D, Whitcup SM, Chan CC. Primary intraocular lymphoma with a low interleukin 10 to interleukin 6 ratio and heterogeneous IgH gene rearrangement. Arch Ophthalmol. 1999;117:1239-1242.
27. Ongkosuwito JV, Feron EJ, van Doornik CE, et al. Analysis of immunoregulatory cytokines in ocular fluid samples from patients with uveitis. Invest Ophthalmol Vis Sci. 1998;39:2659-2665.
28. Lacomba MS, Martin CM, Chamond RR, Galera JM, Omar M, Estevez EC. Aqueous and serum interferon gamma, interleukin (IL) 2, IL-4, and IL-10 in patients with uveitis. Arch Ophthalmol. 2000;118:768-772.
29. Velez G, Chan CC, Csaky KG. Fluorescein angiographic findings in primary intraocular lymphoma. Retina. 2002;22:37-43.
30. Chan CC, Wallace DJ. Intraocular lymphoma: update on diagnosis and management. Cancer Control. 2004;11:285-295.